SEBULSKY ALAN
CIK: 0001092348
SEBULSKY ALAN's purchase track record
SEBULSKY ALAN has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/11/2026 | PBLS | $724K | +19.8% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PBLS | ▲ Buy | Open Market | 5,000 | $130K | 6/15/2026 | View on chart |
| PBLS | ▲ Buy | Open Market | 4,065 | $110K | 6/15/2026 | View on chart |
| PBLS | ▲ Buy | Open Market | 8,435 | $233K | 6/12/2026 | View on chart |
| PBLS | ▲ Buy | Open Market | 12,500 | $250K | 6/11/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial
Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.
Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial. Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.